ReDO_DB: the repurposing drugs in oncology database.

Pan Pantziarka,Ilse Rooman,Bishal Gyawali,Ciska Verbaanderd,Rica Capistrano,Gauthier Bouche,Lydie Meheus,Vidula Sukhatme,Sergio Crispino,An Mt Van Nuffel,Vikas P Sukhatme

doi:10.3332/ecancer.2018.886

Abstract

Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project.org/db/).

Highlights

Drug repurposing, known as repositioning, is a strategy that seeks new medical treatments from among existing licensed medications rather than from the development of new molecules [1]
This paper introduces ReDO_DB—a database of non-cancer drugs with evidence of anticancer activity that has been developed as part of the Repurposing Drugs in Oncology (ReDO) project
In order to maximise the utility of the database, an open access version is made available online via the website of the ReDO project

Summary

Introduction

Known as repositioning, is a strategy that seeks new medical treatments from among existing licensed medications rather than from the development of new molecules (de novo drug development) [1]. The Repurposing Drugs in Oncology (ReDO) project is an on-going collaborative project that has focused exclusively on the potential use of licensed non-cancer medications as sources of new cancer therapeutics [6] There are very few examples in standard clinical practice of non-cancer drugs being moved into oncology, with thalidomide (multiple myeloma) and all-trans retinoic acid (acute promyelocytic leukaemia) being the best-known examples In this sense, the ReDO project has focused exclusively on hard drug repurposing in oncology

Methods

Results

Discussion

Conclusion